New combo shows promise in slowing advanced breast cancer
NCT ID NCT05963984
First seen Sep 30, 2025 · Last updated May 21, 2026 · Updated 32 times
Summary
This study tested whether adding the drug samuraciclib to standard hormone therapy (fulvestrant) works better than fulvestrant alone for people with a certain type of advanced breast cancer (HR-positive, HER2-negative). The trial included 60 adults whose cancer had worsened despite prior treatment. Researchers measured how many patients had their cancer shrink or stay stable for at least 24 weeks.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Actualidad Basada en la Investigación del Cáncer
Guadalajara, Jalisco, 44280, Mexico
-
Centro de Investigacion Clinica de Oaxaca
Oaxaca City, 68020, Mexico
-
Cryptex Investigación Clínica S.A. de C.V.
Cuauhtémoc, 06100, Mexico
-
Dr. Abdurrahman Yurtaslan Ankara Onkoloji Egitim ve Arastırma Hastanesi
Ankara, 06200, Turkey (Türkiye)
-
Gazi University
Ankara, 06120, Turkey (Türkiye)
-
Gulhane Egitim ve Arastirma Hastanesi
Ankara, 06010, Turkey (Türkiye)
-
Hacettepe Universite Hastaneleri
Ankara, 06230, Turkey (Türkiye)
-
Hospital Clinico San Carlos
Madrid, Madrid, Comunidad de, 28040, Spain
-
Hospital Clinico de Valencia
Valencia, 46010, Spain
-
Hospital Infanta Cristina
Badajoz, 06080, Spain
-
Hospital Universitari Vall d'Hebron
Barcelona, 08035, Spain
-
Hospital Universitario Marqués de Valdecilla
Santander, Cantabria Comunidad de, 39002, Spain
-
Hospital Universitario de Salamanca - Complejo Asistencial Universitario de Salamanca
Salamanca, 37007, Spain
-
Hospital Vithas Málaga
Málaga, 29016, Spain
-
I.E.U. Medical Point Hastanesi
Izmir, 35575, Turkey (Türkiye)
-
Institut Català d'Oncologia - L'Hospitalet
L'Hospitalet de Llobregat, Barcelona, 08908, Spain
-
Istanbul Universitesi Istanbul Tıp Fakultesi Hastanesi
Istanbul, 34093, Turkey (Türkiye)
-
MD Anderson Cancer Center
Madrid, 28015, Spain
-
Mfsmc-Hjwci
Baltimore, Maryland, 21237, United States
-
Nograd Varmegyei Szent Lazar Korhaz
Salgótarján, Nógrád megye, 3100, Hungary
-
Oaxaca Site Management Organization S.C.
Oaxaca City, 68000, Mexico
-
Ocala Oncology Center PL DBA Florida Cancer Affiliates
Ocala, Florida, 34474, United States
-
Parc de Salut Mar - Hospital del Mar
Barcelona, 08003, Spain
-
Renati Innovation S.A.P.I de C.V
Guadalajara, Jalisco, 44680, Mexico
-
Saint Luke's Cancer Institute
Kansas City, Missouri, 64111, United States
-
Semmelweis Egyetem
Budapest, 1082, Hungary
-
Sidney Kimmel Cancer Center - Jefferson Health
Philadelphia, Pennsylvania, 19107, United States
-
Soltmed SMO
Mexico City, Mexico City, 03650, Mexico
-
Szent Borbala Korhaz
Tatabánya, Komárom-Esztergom, 2800, Hungary
-
TC Saglik Bakanligi Goztepe Prof. Dr. Suleyman Yalcin Sehir Hastanesi
Istanbul, 34722, Turkey (Türkiye)
-
The Center for Cancer and Blood Disorders
Fort Worth, Texas, 76104, United States
-
Trakya University
Edirne, 22030, Turkey (Türkiye)
Conditions
Explore the condition pages connected to this study.